Newsfeeds - Spark Newswire

2 minute read

EXCLUSIVE: Longeveron’s Lomecel-B Product Gets US FDA Fast Track Designation For Treatment Of Hypoplastic Left Heart Syndrome in Infants

Today, 4:12 AM

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Longeveron Inc (NASDAQ: LGVN) Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS).

LGVN

1 minute read

EXCLUSIVE: Longeveron’s Heart Disease Cell Therapy Poised To Secure European Patent

By Vandana Singh

Today, 4:12 AM

The European Patent Office has issued a notice of its intent to grant Longeveron Inc (NASDAQ: LGVN) a patent related to methods to treat endothelial dysfunction and monitor the efficacy of allogeneic mesenchymal cell therapies, also known as medicinal signaling cells (MSCs).

LGVN

3 minute read

Uncategorized

LGVN: Quarterly Report Provides Good News

By Zacks Small Cap Research

Today, 4:12 AM

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

LGVN

1 minute read

Earnings

Longeveron: Q2 Earnings Insights

By Benzinga Insights

Today, 4:12 AM

Longeveron (NASDAQ:LGVN) reported its Q2 earnings results on Friday, August 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

LGVN

2 minute read

Earnings

Earnings Scheduled For August 12, 2022

By Benzinga Insights

Today, 4:12 AM

Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million.

AIM

5 minute read

Uncategorized

LGVN: Alzheimer’s Study Gains Traction as CEO Search Continues

By Zacks Small Cap Research

Today, 4:12 AM

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

LGVN

5 minute read

This Low-Float Stock Jumps Around 148%; Here’s 64 Biggest Movers From Yesterday

By Lisa Levin

Today, 4:12 AM

Gainers United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market.

ABEO